Avior Bio is a clinical-stage pharmaceutical company advancing therapies in pruritus (itch) in chronic liver disease (CLD) and atopic dermatitis (eczema). Today, there are no FDA approved therapies for CLD-associated pruritus in the USA, and one very expensive, biological therapeutic injection for eczema, namely Dupixent®. Avior strives to seek the first-to-market status for the targeted indication of CLD-associated pruritus and hopes that its drug will be the standard-of-care in the treatment of pruritus in eczema.
Our lead product – AV104 oral film – is based on small molecule with a unique dual mechanism of action in the treatment of pruritus. There are approximately 2.5 million patients that suffer from pruritus in chronic liver disease and approximately 15.6 million patients that suffer from pruritus in eczema. Both indication represents a significant market opportunity for AV104.